(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...

Equities research analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on ...

At the recent SEC meeting for Endocrinology and Metabolism held on 13th January 2025, the expert panel reviewed the ...

If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...